Boston, MA, United States of America

Bo Chen

This inventor holds 7 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignee: Genzyme Corporation. Active years: 2017-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Bo Chen. Retrieved from https://idiyas.com/inventor/bo-chen-j7opoe2z

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 7 

% Patents Active = 100.0

 

Average Co-Inventor Count = 6.4

ph-index = 4

Forward Citations = 45(Granted Patents)


Company Filing History:


Years Active: 2017-2024

Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: Innovator Bo Chen: Pioneering Advances in Antibody-Drug Conjugate Technology

Introduction

Bo Chen, a renowned inventor based in Boston, MA, has significantly contributed to the field of biotechnology with a focus on antibody-drug conjugates (ADCs). With a total of seven patents to his name, Chen's work is instrumental in the development of therapeutic agents for various diseases. His innovative research aims at enhancing the effectiveness of cancer treatments through advanced glycoengineering techniques.

Latest Patents

Among his latest patents, Chen's work on "Site-specific antibody-drug conjugation through glycoengineering" stands out. This patent outlines binding polypeptides, such as antibodies, and their conjugates, which feature a site-specifically engineered drug-glycan linkage. This innovation provides a method for creating antigen-binding polypeptides and outlines the use of these polypeptides in treating diseases.

Another notable patent is for "Hyperglycosylated binding polypeptides." This patent describes binding polypeptides that incorporate an engineered N-linked glycosylation site within a specific domain of the antibody. It also includes methods for utilizing these engineered polypeptides in clinical applications, further advancing the landscape of targeted therapeutics.

Career Highlights

Bo Chen is currently making strides in his role at Genzyme Corporation, a leading biotechnology company known for its pioneering work in rare genetic diseases and digestive health. His research within the company has led to significant advances in drug development through innovative applications of biochemistry and genetic engineering, marking important milestones in the field.

Collaborations

Chen's work often involves collaboration with fellow researchers, contributing to a vibrant intellectual exchange that fosters innovation. Notable colleagues include Clark Qun Pan and Huawei Qiu, who share a commitment to advancing the frontiers of biotechnology. Their collaborative efforts enhance the potential of their research projects, leading to impactful advancements in medical treatments.

Conclusion

Bo Chen’s inventive spirit and dedication to biotechnological advancements make him a pivotal figure in the realm of antibody-drug conjugates. His contributions to the industry through his patents not only exemplify his expertise but also lay the groundwork for future innovations that promise to revolutionize therapeutic techniques in medicine. As research continues to evolve, Chen's work remains vital in the ongoing quest for effective disease treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…